Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 15/20 | 0.62 |
| ▸ | SLC9A5 | Q14940 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460538 | 1.00 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| N,N-Hexamethyleneamiloride SCHEMBL29384339 | 1.00 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11469206 | 0.99 | PLAU (0.60) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL26104614 | 0.88 | ALDH1A1 (0.47) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11615921 | 0.85 | PLAU (0.53) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL15082596 | 0.84 | PLAU (0.57) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| Amiloride SCHEMBL365969 | 0.82 | SCNN1A (0.55) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL17704667 | 0.82 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11467427 | 0.80 | GRM5 (0.48) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL26106945 | 0.80 | GRM5 (0.58) | PLAUSLC9A5LMNANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-11-02 | — | — | US | disclosed |
| US-20200368229-A9 | Methods for Treating HCV | ABBVIE INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200330460-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-08-06 | — | — | US | disclosed |
| US-20200222397-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2020-05-19 | — | — | US | disclosed |
| EP-3318258-B1 | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS | ABBVIE INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10286029-B2 | Method for treating HCV | ABBVIE INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | THE HOSPITAL FOR SICK CHILDREN (CA) | 2018-07-24 | — | — | US | disclosed |
| US-20130102557-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2013-04-11 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-8124597-B2 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120021487-A1 | METHOD OF TREATING GAUCHER DISEASE | MCMASTER UNIVERSITY (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20090075960-A1 | Method of treating gaucher disease | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-03-19 | — | — | US | disclosed |
| US-5260091-A | Sodium chloride and amiloride | INTERNEURON PHARMACEUTICALS INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075960-A1 | Method of treating gaucher disease | GBA1, GAA, GBA3 | PLAU 3089/4885SLC9A5 3661/4885LMNA 731/4885 |
| US-20200246282-A1 | Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase | GBA1, GBA3, GAA | PLAU 3417/4885SLC9A5 1612/4885LMNA 1185/4885 |
| US-10653645-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | PLAU 3417/4885SLC9A5 1612/4885LMNA 1185/4885 |
| US-11160773-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | PLAU 3417/4885SLC9A5 1612/4885LMNA 1185/4885 |
| US-20200368229-A9 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | PLAU 1201/4885SLC9A5 2513/4885LMNA 4747/4885 |
| US-20130090388-A1 | METHOD OF TREATING GAUCHER DISEASE | GBA1, GAA, GBA3 | PLAU 3089/4885SLC9A5 3661/4885LMNA 731/4885 |
| US-20130102557-A1 | Methods for Treating HCV | HAVCR2, EIF2AK2, IFNAR1 | PLAU 1074/4885SLC9A5 4473/4885LMNA 4694/4885 |
| US-10286029-B2 | Method for treating HCV | EIF2AK2, IFNG, IFNAR1 | PLAU 1149/4885SLC9A5 2230/4885LMNA 4784/4885 |
| US-20200222397-A1 | Methods for Treating HCV | EIF2AK2, IFNG, IFNAR1 | PLAU 923/4885SLC9A5 2036/4885LMNA 4767/4885 |
| US-20200330460-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | PLAU 1201/4885SLC9A5 2513/4885LMNA 4747/4885 |
| US-10028922-B2 | Method for enhancing folding and transport of misfolded glucocerebrosidase | GBA1, GBA3, GAA | PLAU 3417/4885SLC9A5 1612/4885LMNA 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.